BriaCell Therapeutics Corp.
NASDAQ:BCTX
5.2 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.083 | 0.02 | 0.019 | 0.019 | 0.019 | 0.019 | 0.017 | 0 | 0.002 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.083 | -0.02 | -0.019 | -0.019 | -0.019 | -0.019 | -0.017 | -0 | -0.002 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 26.752 | 15.337 | 8.021 | 1.315 | 2.221 | 3.74 | 2.389 | 1.706 | 0.723 | 0.106 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 7.936 | 7.267 | -3.675 | -1.371 | -0.932 | -1.052 | 0.876 | 0.942 | 1.334 | 0.436 | 0.424 | 0.556 | 1.051 | 0.323 | 0.204 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.973 | 7.936 | 7.267 | -3.675 | -1.371 | -0.932 | -1.052 | 0.876 | 0.942 | 1.334 | 0.436 | 0.424 | 0.556 | 1.051 | 0.323 | 0.204 | 0.114 | 0.129 | 0.009 |
| Other Expenses
| 0 | 0 | -15.292 | -1.331 | -2.235 | -3.754 | -0.313 | 0 | 0.001 | 0 | 0.001 | 0 | -0.004 | 0.003 | 0.001 | 0.002 | 0 | 0 | 0 |
| Operating Expenses
| 32.726 | 23.272 | -0.003 | -3.69 | -1.385 | -0.946 | -1.065 | 2.582 | 1.667 | 1.44 | 0.437 | 0.424 | 0.552 | 1.053 | 0.325 | 0.234 | 0.114 | 0.129 | 0.009 |
| Operating Income
| -32.808 | -23.272 | -15.289 | 3.69 | 1.385 | 0.946 | -3.819 | -2.582 | -1.667 | -1.44 | -0.437 | -0.424 | -1.198 | -1.053 | -0.325 | -0.234 | -0.114 | -0.129 | -0.009 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 27.954 | 2.97 | -18.778 | -6.843 | -0.085 | 0.905 | -1.593 | -0.002 | -0.038 | -1.241 | -7.709 | 0.056 | -0.437 | 0.024 | -0.579 | -0.012 | 0 | 0 | 0 |
| Income Before Tax
| -4.854 | -20.302 | -11.55 | 3.69 | 1.385 | 0.946 | 1.065 | -2.584 | -1.696 | -2.682 | -8.146 | -0.369 | -0.996 | -1.092 | -0.904 | -0.232 | 0 | 0 | 0 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.153 | 0.031 | 6.584 | -0.072 | 0.344 | -0.319 | 0.002 | 0.029 | 1.241 | 7.709 | -0.056 | 0.444 | 0.026 | 0.576 | -0.003 | 0.099 | 0.116 | 0.009 |
| Net Income
| -4.716 | -20.302 | -11.581 | -2.895 | 1.385 | 0.603 | 1.065 | -2.584 | -1.696 | -2.682 | -8.146 | -0.369 | -0.996 | -1.079 | -0.901 | -0.229 | -0.099 | -0.116 | -0.009 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.29 | -1.74 | -0.75 | -0.19 | 1.94 | 1.04 | 2.49 | -7.61 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EPS Diluted
| -0.29 | -1.74 | -0.75 | -0.19 | 1.94 | 1.04 | 2.49 | -7.32 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EBITDA
| -4.772 | -27.221 | -34.047 | -17.487 | -4.889 | -5.74 | -5.375 | -3.22 | -2.213 | -3.488 | -8.886 | -0.379 | -0.996 | -1.027 | -0.925 | -0.246 | -0.114 | -0.129 | -0.009 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |